Alembic receives USFDA final approval for Nifedipine Extended-Release Tablets
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.
Subscribe To Our Newsletter & Stay Updated